Various proteins play a decisive role in the pathology of different neurodegenerative diseases. Nonetheless, most of these proteins can only be detected during a neuropathological assessment, although some non-specific biomarkers are routinely tested for in the cerebrospinal fluid (CSF) as a part of the differential diagnosis of dementia. In antemortem CSF samples from 117 patients with different types of neuropathologically confirmed neurodegenerative disease with dementia, we assessed total-tau (t-tau), phosphorylated-tau (181P) (p-tau), amyloid-beta (1-42) (Aβ42), TAR DNA binding protein (TDP)-43, progranulin (PGRN), and neurofilament light (NfL) chain levels, and positivity of protein 14-3-3. We found t-tau levels and the t-tau/p-tau ratios were significantly higher in prion diseases compared to the other neurodegenerative diseases. Statistically significant differences in the t-tau/Aβ42 ratio predominantly corresponded to t-tau levels in prion diseases and Aβ42 levels in AD. TDP-43 levels were significantly lower in prion diseases. Additionally, the TDP-43/Aβ42 ratio was better able to distinguish Alzheimer's disease from other neurodegenerative diseases compared to using Aβ42 alone. In frontotemporal lobar degeneration, PRGN levels were significantly higher in comparison to other neurodegenerative diseases. There is an increasing need for biomarkers suitable for diagnostic workups for neurodegenerative diseases. It appears that adding TDP-43 and PGRN to the testing panel for neurodegenerative diseases could improve the resolution of differential diagnoses.

Department of Neurology 3rd Faculty of Medicine Charles University and Thomayer University Hospital Prague Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University and Thomayer University Hospital Videnska 800 14059 Prague 4 Krc Czech Republic

Zobrazit více v PubMed

Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases. Alzheimers Res. Ther. 2009;1:5. doi: 10.1186/alzrt5. PubMed DOI PMC

Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest. 2013;123:1847–1855. doi: 10.1172/JCI66029. PubMed DOI PMC

Forman MS, Trojanowski JQ, Lee VM-Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004;10:1055–1106. doi: 10.1038/nm1113. PubMed DOI

Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat. Med. 2004;10(Suppl):S10–S17. doi: 10.1038/nm1066. PubMed DOI

Budka H, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases) Brain Pathol. 1995;5:459–466. doi: 10.1111/j.1750-3639.1995.tb00625.x. PubMed DOI

Kovacs GG, Budka H. Molecular pathology of human prion diseases. Int. J. Mol. Sci. 2009;10:976–999. doi: 10.3390/ijms10030976. PubMed DOI PMC

Kovacs GG, et al. Tau pathology in Creutzfeldt-Jakob disease revisited. Brain Pathol. 2016;27:332–344. doi: 10.1111/bpa.12411. PubMed DOI PMC

Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017;6:2053. doi: 10.12688/f1000research.12681.1. PubMed DOI PMC

Clark CM, et al. Cerebrospinal fluid tau and β-amyloid how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 2003;60:1696–1702. doi: 10.1001/archneur.60.12.1696. PubMed DOI

Scherling CS, et al. CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 2014;75:116–126. doi: 10.1002/ana.24052. PubMed DOI PMC

McKhann GM, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. PubMed DOI PMC

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944. doi: 10.1212/wnl.34.7.939. PubMed DOI

Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res. Ther. 2014;6:46. doi: 10.1186/alzrt274. PubMed DOI PMC

Garcia-Esparcia P, et al. Dementia with Lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms. Front. Neurol. 2017;8:89. doi: 10.3389/fneur.2017.00089. PubMed DOI PMC

Hall S, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012;69:1445–1452. doi: 10.1001/archneurol.2012.1654. PubMed DOI

Snowden JS, Neary D, Mann DMA. Frontotemporal dementia. Br. J. Psychiatry. 2002;180:140–143. doi: 10.1192/bjp.180.2.140. PubMed DOI

Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919. doi: 10.1038/nature05016. PubMed DOI

Goedert M, Ghetti B, Spillantini MG. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006254. doi: 10.1101/cshperspect.a006254. PubMed DOI PMC

Goossens J, et al. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimers Res. Ther. 2018;10:31. doi: 10.1186/s13195-018-0364-0. PubMed DOI PMC

King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61–80. doi: 10.1016/j.brainres.2012.01.016. PubMed DOI PMC

Davis SA, et al. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8–15. doi: 10.1016/j.neulet.2018.04.053. PubMed DOI PMC

Zhang Y-J, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. Neurosci. 2007;27:10530–10534. doi: 10.1523/JNEUROSCI.3421-07.2007. PubMed DOI PMC

Davidson Y, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol. 2007;113:521–533. doi: 10.1007/s00401-006-0189-y. PubMed DOI

Igaz LM, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J. Biol. Chem. 2009;284:8516–8524. doi: 10.1074/jbc.M809462200. PubMed DOI PMC

Van Damme P, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 2008;181:37–41. doi: 10.1083/jcb.200712039. PubMed DOI PMC

Ahmed Z, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 2010;177:311–324. doi: 10.2353/ajpath.2010.090915. PubMed DOI PMC

Rademakers R, Neumann M, Mackenzie IRA. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 2012;8:423–434. doi: 10.1038/nrneurol.2012.117. PubMed DOI PMC

Meeter LHH, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement. Geriatr. Cogn. Disord. Extra. 2016;6:330–340. doi: 10.1159/000447738. PubMed DOI PMC

Chang MC, et al. Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. J. Exp. Med. 2017;214:2611–2628. doi: 10.1084/jem.20160999. PubMed DOI PMC

Bacioglu M, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56–66. doi: 10.1016/j.neuron.2016.05.018. PubMed DOI

Olsson B, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76:318–325. doi: 10.1001/jamaneurol.2018.3746. PubMed DOI PMC

Fialová L, Bartoš A, Švarcová J. Neurofilament light chains in serum and cerebrospinal fluid and status of blood-CSF barrier in the selected neurological diseases. Cesk. Slov. Neurol. N. 2018;81:185–192. doi: 10.14735/amcsnn2018185. DOI

Gaetani L, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol. Neurosurg. Psychiatry. 2019;90:870–881. doi: 10.1136/jnnp-2018-320106. PubMed DOI

CDC. CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD). (2018). Available at: https://www.cdc.gov/prions/cjd/diagnostic-criteria.html. Accessed 29 Oct 2020.

Hu WT, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology. 2010;75:2079–2086. doi: 10.1212/WNL.0b013e318200d78d. PubMed DOI PMC

Hales CM, Hu WT. From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int. Rev. Psychiatry. 2013;25:210–220. doi: 10.3109/09540261.2013.776522. PubMed DOI

Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? Neurol. Neurosurg. Psychiatry. 2001;71:401–403. doi: 10.1136/jnnp.71.3.401. PubMed DOI PMC

Riemenschneider M, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry. 2003;8:343–347. doi: 10.1038/sj.mp.4001220. PubMed DOI

Teunissen CE, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914–1922. doi: 10.1212/WNL.0b013e3181c47cc2. PubMed DOI PMC

Willemse EA, Koel-Simmelink MJ, Durieux-Lu S, van der Flier WM, Teunissen CE. Standard biobanking conditions prevent evaporation of body fluid samples. Clin. Chim. Acta. 2015;442:141–145. doi: 10.1016/j.cca.2015.01.036. PubMed DOI

Green AJ, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry. 2001;70:744–748. doi: 10.1136/jnnp.70.6.744. PubMed DOI PMC

Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin. Neuropathol. 2010;29:271–288. doi: 10.5414/npp29271. PubMed DOI

Montine TJ, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123:1–11. doi: 10.1007/s00401-011-0910-3. PubMed DOI PMC

Williams DR, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain. 2007;130:1566–1576. doi: 10.1093/brain/awm104. PubMed DOI

Kovacs GG, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99–119. doi: 10.1007/s00401-020-02158-2. PubMed DOI PMC

Mackenzie IRA, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111–113. doi: 10.1007/s00401-011-0845-8. PubMed DOI PMC

McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89:88–100. doi: 10.1212/WNL.0000000000004058. PubMed DOI PMC

Bahl JM, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol. Aging. 2009;30:1834–1841. doi: 10.1016/j.neurobiolaging.2008.01.013. PubMed DOI

Blennow K, Vanmechelen E, Hampel H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol. 2001;24:87–97. doi: 10.1385/MN:24:1-3:087. PubMed DOI

Sjögren M, et al. Both total and phosphorylated tau are increased in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2001;70:624–630. doi: 10.1136/jnnp.70.5.624. PubMed DOI PMC

Skillbäck T, et al. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease. JAMA Neurol. 2014;71:476–483. doi: 10.1001/jamaneurol.2013.6455. PubMed DOI

Struyfs H, et al. Cerebrospinal fluid P-tau181P: biomarker for improved differential dementia diagnosis. Front. Neurol. 2015;6:138. doi: 10.3389/fneur.2015.00138. PubMed DOI PMC

Bartoš A, Smětáková M, Říčný J, Nosková L, Fialová L. Determination of tau proteins and β-amyloid 42 in cerebrospinal fluid by ELISA methods and preliminary normative values. Cesk. Slov. Neurol. N. 2019;82:533–540. doi: 10.14735/amcsnn2019533. DOI

Hu WT, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945–1952. doi: 10.1212/01.wnl.0000436625.63650.27. PubMed DOI PMC

Borroni B, et al. CSF p-Tau181/Tau ratio as biomarker for TDP pathology in Frontotemporal Dementia. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2015;16:86–91. doi: 10.3109/21678421.2014.971812. PubMed DOI

Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (Amst) 2015;1:505–512. doi: 10.1016/j.dadm.2015.11.001. PubMed DOI PMC

Irwin DJ, et al. Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD. Ann. Neurol. 2017;82:247–258. doi: 10.1002/ana.24996. PubMed DOI PMC

Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009;65:403–413. doi: 10.1002/ana.21610. PubMed DOI PMC

Bian H, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827–1835. doi: 10.1212/01.wnl.0000311445.21321.fc. PubMed DOI PMC

Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov. Disord. 1998;13:70–77. doi: 10.1002/mds.870130116. PubMed DOI

Sjögren M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 2001;66:510–516. doi: 10.1002/jnr.1242. PubMed DOI

Landqvist Waldö M, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 2013;13:54. doi: 10.1186/1471-2377-13-54. PubMed DOI PMC

Abu-Rumeileh S, et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J. Neurol. Neurosurg. Psychiatry. 2020;91:1181–1188. doi: 10.1136/jnnp-2020-323826. PubMed DOI

Sjögren M, et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54:1960–1964. doi: 10.1212/wnl.54.10.1960. PubMed DOI

Isaacs AM, et al. Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol. Appl. Neurobiol. 2008;34:446–456. doi: 10.1111/j.1365-2990.2008.00963.x. PubMed DOI PMC

Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 2007;61:435–445. doi: 10.1002/ana.21154. PubMed DOI PMC

Higashi S, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007;1184:284–294. doi: 10.1016/j.brainres.2007.09.048. PubMed DOI

Nakashima-Yasuda H, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221–229. doi: 10.1007/s00401-007-0261-2. PubMed DOI

Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol. Neurobiol. 2018;55:7789–7801. doi: 10.1007/s12035-018-0947-6. PubMed DOI PMC

Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90. doi: 10.1186/s12883-018-1091-7. PubMed DOI PMC

Körtvélyessy P, et al. Progranulin and amyloid-β levels: relationship to neuropsychology in frontotemporal and Alzheimer’s disease. J. Alzheimers Dis. 2015;46:375–380. doi: 10.3233/JAD-150069. PubMed DOI

Zerr I, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659–2668. doi: 10.1093/brain/awp191. PubMed DOI PMC

Collins SJ, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain. 2006;129:2278–2287. doi: 10.1093/brain/awl159. PubMed DOI

Cuadrado-Corrales N, et al. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol. 2006;6:25. doi: 10.1186/1471-2377-6-25. PubMed DOI PMC

Rohan Z, Smetakova M, Kukal J, Rusina R, Matej R. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases. BMC Neurol. 2015;15:50. doi: 10.1186/s12883-015-0300-x. PubMed DOI PMC

Sanchez-Juan P, et al. CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology. 2006;67:637–643. doi: 10.1212/01.wnl.0000230159.67128.00. PubMed DOI

Hamlin C, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt–Jakob disease. Neurology. 2012;79:547–552. doi: 10.1212/WNL.0b013e318263565f. PubMed DOI PMC

Peng L, Bi C, Xia D, Mao L, Qian H. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Mult. Scler. Relat. Disord. 2019;30:123–128. doi: 10.1016/j.msard.2019.02.009. PubMed DOI

Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for dementia with Lewy bodies. Int. J. Alzheimers Dis. 2010;2010:536538. doi: 10.4061/2010/536538. PubMed DOI PMC

Oeckl P, Steinacker P, Feneberg E, Otto M. Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. J. Neurochem. 2016;138:184–192. doi: 10.1111/jnc.13669. PubMed DOI

Mehta PD, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch. Neurol. 2000;57:100–105. doi: 10.1001/archneur.57.1.100. PubMed DOI

Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet. 2020;19:422–433. doi: 10.1016/S1474-4422(20)30071-5. PubMed DOI

Jack CR, Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. PubMed DOI PMC

Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status

Biomarkers Analysis and Clinical Manifestations in Comorbid Creutzfeldt-Jakob Disease: A Retrospective Study in 215 Autopsy Cases

Human Prion Disorders: Review of the Current Literature and a Twenty-Year Experience of the National Surveillance Center in the Czech Republic